Evidence map›Paper›PMID 42701371›Full record

ArticleMaterials today. Bio2026

Surface-engineered milk-derived extracellular vesicles enable oral miRNA therapy against immunosuppressive pancreatic cancer.

Youngri Ryu, Hochung Jang, Eun Hye Kim, Junha Lee, Byeongmin Park, Yewon Cho, Wonjun Kim, Hong-Yeol Yoon, Sun Hwa Kim, Dae-Hyuk Kweon and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Youngri RyuDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Hochung JangDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Eun Hye KimDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Junha LeeDepartment of MetaBioHealth, School of Medicine, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Byeongmin ParkMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Yewon ChoDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Wonjun KimDepartment of MetaBioHealth, School of Medicine, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Hong-Yeol YoonMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Sun Hwa KimMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Dae-Hyuk KweonDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Man Kyu ShimMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Yoosoo YangDepartment of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) shows limited responsiveness to conventional therapies due to an immunosuppressive tumor microenvironment (TME) characterized by programmed death-ligand 1 (PD-L1)-mediated immune escape and oncogenic microRNA-21 (miR-21) signaling. Despite the potential of miRNA therapeutics, their clinical translation is hindered by the lack of stable, non-invasive delivery systems capable of bypassing complex biological barriers. Here, we develop a scalable biogenic delivery platform based on surface-engineered milk-derived extracellular vesicles (MEVs) for systemic transport of anti-miR-21 (α21) after oral administration. MEVs were isolated using a reproducible purification workflow and functionalized with a PD-L1-binding peptide (PBP) to facilitate tumor-associated uptake while preserving vesicle integrity and colloidal stability. The engineered vesicles (α21@MEV

Indexed as

Cancer immunotherapyMicroRNA-21Milk-derived extracellular vesicleOral drug deliveryPancreatic ductal adenocarcinoma

Identifiers

PMID42701371
PMCPMC13545355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.